0 CHECKOUT

Global Cancer Vaccine Partnering 2010-2015: Deal trends, players, financials and forecasts

  • ID: 3292819
  • July 2015
  • Region: Global
  • 336 Pages
  • CurrentPartnering

The Global Cancer Vaccine Partnering 2010-2015 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value

The Global Cancer Vaccine Partnering 2010-2015 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the READ MORE >

Note: Product cover images may vary from those shown

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer vaccine dealmaking

2.1. Introduction
2.2. Cancer vaccine partnering over the years
2.3. Cancer vaccine partnering by deal type
2.4. Cancer vaccine partnering by industry sector
2.5. Cancer vaccine partnering by stage of development
2.6. Cancer vaccine partnering by cancer indication

Chapter 3 - Average financial deal terms for cancer vaccine partnering
3.1. Introduction
3.2. Disclosed financials terms for cancer vaccine partnering
3.2.1.Cancer vaccine partnering headline values
3.2.2. Cancer vaccine deal upfront payments
3.2.3. Cancer vaccine deal milestone payments
3.2.4. Cancer vaccine royalty rates

Chapter 4 - Leading cancer vaccine deals
4.1. Introduction
4.2. Most active in cancer vaccine partnering
4.3. Top cancer vaccine deals by value
4.4. Big pharma cancer vaccine dealmaking activity

Chapter 5 - Cancer vaccine dealmaking contracts directory
5.1. Introduction
5.2. Cancer vaccine deals by company A-Z
5.3. Cancer vaccine deals by stage of development
5.4. Cancer vaccine deals by deal type

Chapter 6 - Cancer vaccine dealmaking by specific therapy type
6.1. Introduction
6.2. Deals by oncology type

Chapter 7 - Cancer vaccine dealmaking by specific technology type
7.1. Introduction
7.2. Deals by adjuvant and vaccines type

Chapter 8 - Future trends and companies in cancer vaccine deal making
8.1. Introduction
8.2. Emerging companies to watch in 2015
8.3 Emerging companies dealmaking in 2010-2015
8.4. Emerging company financings in 2010-2015
8.5 Conclusion
Appendices
Introduction
Appendix 1 - Directory of cancer vaccine deals by company A-Z 2010-2015
Appendix 2 - Directory of cancer vaccine deals by stage of development 2010-2015
Appendix 3 - Directory of cancer vaccine deals by deal type 2010-2015

Chapter 9 -Partnering resource center
9.1. Online partnering
9.2. Partnering events
9.3. Further reading on dealmaking
About
Recent report titles

List of figures:
Figure 1: Cancer vaccine partnering since 2010
Figure 2: Cancer vaccine partnering by deal type since 2010
Figure 3: Cancer vaccine partnering by industry sector since 2010
Figure 4: Cancer vaccine partnering by stage of development since 2010
Figure 5: Cancer vaccine partnering by oncology target since 2010
Figure 6: Cancer vaccine deals with a headline value - by stage of development
Figure 7: Cancer vaccine deals with upfront payment values - by stage of development
Figure 8: Cancer vaccine deals with milestone payment - by stage of development
Figure 9: Cancer vaccine deals with royalty rates
Figure 10: Active cancer vaccine dealmaking activity- 2010 to 2015
Figure 11: Top cancer vaccine by value since 2010
Figure 12: Big pharma - top 50 - Cancer vaccine deals 2010 to 2015
Figure 13: Big pharma cancer vaccine deal frequency - 2010 to 2015
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events

Note: Product cover images may vary from those shown

Key benefits:

Global Cancer Vaccine Partnering 2010-2015: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

- In-depth understanding of cancer vaccine deal trends since 2010

- Access to headline, upfront, milestone and royalty data

- Access to the structure of cancer vaccine agreements with numerous real life case studies

- Comprehensive access to over 150 actual cancer vaccine deals entered into by the world’s biopharma companies

- Insight into the terms included in a cancer vaccine agreement, together with real world clause examples

- Understand the key deal terms companies have agreed in previous deals

- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: A copy of the report will be emailed to you and a copy will be shipped to you in CD ROM format. The Electronic copy is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S